Abstract
Since 2012, the Network Genomic Medicine (NGM) has been providing alarge number of lung cancer patients from referring partner sites with comprehensive molecular-pathological diagnostics on the single diagnostic platform at the University Hospital Cologne. In addition, the network headquarters in Cologne interprets the findings in close interdisciplinary coordination between pathologists and oncologists, provides information on innovative treatment options, and evaluates the personalized therapies using the central database. As part of one of its largest single grants in 2018, the German Cancer Aid (DKH) rolled out this interdisciplinary and intersectoral care model to all existing DKH-funded German comprehensive cancer centers at the time of the initial application. Presentation of the treatment reality within the national Network Genomic Medicine (nNGM) with its core elements and actors (network centers and intersectoral clinical partners sites). This article is based on our own experience in NGM and nNGM and includes asummary of the currently applicable guidelines for reimbursement and an overview of the treatment landscape in the field of molecular-pathological diagnostics in Germany. The focus of nNGM is on the implementation of innovative molecular diagnostics and personalized therapy in broad clinical routine in Germany. This is enabled by developing molecular-pathological diagnostics within the network centers on an ongoing basic, interdisciplinary counseling of referring partner sites, offering innovative clinical trials, and performing central evaluation. In particular, afocus of nNGM is the development of regional networks to treat the affected lung cancer patients close to home at the partner sites whenever possible. Interdisciplinary teams are essential for the success of abroad implementation of molecular-pathological diagnostics. nNGM addresses asevere deficit in German lung cancer care and in the future will be expanded to further network centers while meeting the defined quality criteria.
Highlights
Since 2012, the Network Genomic Medicine (NGM) has been providing a large number of lung cancer patients from referring partner sites with comprehensive molecular-pathological diagnostics on the single diagnostic platform at the University Hospital Cologne
This article is based on our own experience in NGM and national Network Genomic Medicine (nNGM) and includes a summary of the currently applicable guidelines for reimbursement and an overview of the treatment landscape in the field of molecular-pathological diagnostics in Germany
The focus of nNGM is on the implementation of innovative molecular diagnostics and personalized therapy in broad clinical routine in Germany
Summary
Seit seiner Gründung im Jahre 2012 versorgt das Netzwerk Genomische Medizin (NGM) nun ca. 10 % aller jährlich in Deutschland neu diagnostizierten, fortgeschrittenen Lungenkrebspatienten zentral im Institut für Pathologie der Uniklinik Köln mit modernster molekularpathologischer Diagnostik, informiert in enger interdisziplinärer Zusammenarbeit mit der Kölner LungenkrebsStudiengruppe (LCGC) über die Behandlungsmöglichkeiten mit zugelassenen Therapien entweder im Rahmen von Off-label-Therapien oder bevorzugt in laufenden klinischen Studien mit neuesten zielgerichteten Medikamenten. 10 % aller jährlich in Deutschland neu diagnostizierten, fortgeschrittenen Lungenkrebspatienten zentral im Institut für Pathologie der Uniklinik Köln mit modernster molekularpathologischer Diagnostik, informiert in enger interdisziplinärer Zusammenarbeit mit der Kölner LungenkrebsStudiengruppe (LCGC) über die Behandlungsmöglichkeiten mit zugelassenen Therapien entweder im Rahmen von Off-label-Therapien oder bevorzugt in laufenden klinischen Studien mit neuesten zielgerichteten Medikamenten. Das NGM bietet für weitere Indikationen neue eigeninitiierte klinische Studien und begleitet alle Patienten über die intersektoralen Netzwerkpartner (Krankenhäuser und Praxen) mit dem Ziel, weitere moderne Therapieverfahren ortsnah in der flächendeckenden onkologischen Versorgung anzubieten. Kernelemente des nationalen Netzwerks Genomische Medizin (nNGM) sind die fortlaufende Weiterentwicklung molekularpathologischer Diagnostik innerhalb der Institute für Pathologie der Netzwerkzentren, der Aufbau regionaler Netzwerke zur Anbindung möglichst vieler klinischer Netzwerkpartner, die interdisziplinäre Analytik, zentrale Evaluation, Beratung und gemeinsame Therapieplanung für die Patienten sowie die rasche Weiterentwicklung klinischer Studien für neue individualisierte Behandlungsansätze
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
